CA2224859A1 - Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor - Google Patents
Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor Download PDFInfo
- Publication number
- CA2224859A1 CA2224859A1 CA002224859A CA2224859A CA2224859A1 CA 2224859 A1 CA2224859 A1 CA 2224859A1 CA 002224859 A CA002224859 A CA 002224859A CA 2224859 A CA2224859 A CA 2224859A CA 2224859 A1 CA2224859 A1 CA 2224859A1
- Authority
- CA
- Canada
- Prior art keywords
- insulin
- growth factor
- igf
- igfbp
- ligand inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 109
- 239000003446 ligand Substances 0.000 title claims abstract description 90
- 102000028416 insulin-like growth factor binding Human genes 0.000 title claims abstract description 55
- 108091022911 insulin-like growth factor binding Proteins 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 39
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract description 80
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims abstract description 62
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 46
- 230000027455 binding Effects 0.000 claims abstract description 42
- 102000013275 Somatomedins Human genes 0.000 claims abstract description 34
- 150000003384 small molecules Chemical class 0.000 claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 28
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims abstract description 18
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims abstract description 18
- 230000001965 increasing effect Effects 0.000 claims abstract description 14
- 210000004369 blood Anatomy 0.000 claims description 32
- 239000008280 blood Substances 0.000 claims description 32
- 102000014914 Carrier Proteins Human genes 0.000 claims description 26
- 108091008324 binding proteins Proteins 0.000 claims description 26
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 claims description 21
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 claims description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims description 14
- 210000004556 brain Anatomy 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 claims description 4
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 claims description 4
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 claims description 4
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 claims description 4
- 102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 claims description 4
- 108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 claims description 4
- 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 claims description 4
- 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 206010053759 Growth retardation Diseases 0.000 claims description 2
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 2
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 2
- 239000000854 Human Growth Hormone Substances 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 231100000001 growth retardation Toxicity 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 claims 3
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 claims 3
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 93
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 59
- 102000044162 human IGF1 Human genes 0.000 description 34
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- 239000008103 glucose Substances 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 23
- 238000011282 treatment Methods 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 15
- 108090001061 Insulin Proteins 0.000 description 15
- 229940125396 insulin Drugs 0.000 description 15
- 238000003556 assay Methods 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000006820 DNA synthesis Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 108010016616 cysteinylglycine Proteins 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101710125089 Bindin Proteins 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- HKXSZKJMDBHOTG-CIUDSAMLSA-N Lys-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN HKXSZKJMDBHOTG-CIUDSAMLSA-N 0.000 description 3
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- SUMYEVXWCAYLLJ-GUBZILKMSA-N Ala-Leu-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O SUMYEVXWCAYLLJ-GUBZILKMSA-N 0.000 description 2
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 2
- DBKNLHKEVPZVQC-LPEHRKFASA-N Arg-Ala-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O DBKNLHKEVPZVQC-LPEHRKFASA-N 0.000 description 2
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- XABFFGOGKOORCG-CIUDSAMLSA-N Cys-Asp-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XABFFGOGKOORCG-CIUDSAMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ININBLZFFVOQIO-JHEQGTHGSA-N Gln-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O ININBLZFFVOQIO-JHEQGTHGSA-N 0.000 description 2
- MXPBQDFWIMBACQ-ACZMJKKPSA-N Glu-Cys-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O MXPBQDFWIMBACQ-ACZMJKKPSA-N 0.000 description 2
- MFVQGXGQRIXBPK-WDSKDSINSA-N Gly-Ala-Glu Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFVQGXGQRIXBPK-WDSKDSINSA-N 0.000 description 2
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 2
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
- BCISUQVFDGYZBO-QSFUFRPTSA-N Ile-Val-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O BCISUQVFDGYZBO-QSFUFRPTSA-N 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- CGHXMODRYJISSK-NHCYSSNCSA-N Leu-Val-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O CGHXMODRYJISSK-NHCYSSNCSA-N 0.000 description 2
- BOJYMMBYBNOOGG-DCAQKATOSA-N Lys-Pro-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BOJYMMBYBNOOGG-DCAQKATOSA-N 0.000 description 2
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 2
- JEGFCFLCRSJCMA-IHRRRGAJSA-N Phe-Arg-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N JEGFCFLCRSJCMA-IHRRRGAJSA-N 0.000 description 2
- KAHUBGWSIQNZQQ-KKUMJFAQSA-N Phe-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KAHUBGWSIQNZQQ-KKUMJFAQSA-N 0.000 description 2
- DXWNFNOPBYAFRM-IHRRRGAJSA-N Phe-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N DXWNFNOPBYAFRM-IHRRRGAJSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ODXKUIGEPAGKKV-KATARQTJSA-N Thr-Leu-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)N)O ODXKUIGEPAGKKV-KATARQTJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 108010079413 glycyl-prolyl-glutamic acid Proteins 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241001416152 Bos frontalis Species 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JPVGHHQGKPQYIL-KBPBESRZSA-N Gly-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 JPVGHHQGKPQYIL-KBPBESRZSA-N 0.000 description 1
- QAMMIGULQSIRCD-IRXDYDNUSA-N Gly-Phe-Tyr Chemical compound C([C@H](NC(=O)C[NH3+])C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C([O-])=O)C1=CC=CC=C1 QAMMIGULQSIRCD-IRXDYDNUSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- IFMPDNRWZZEZSL-SRVKXCTJSA-N Leu-Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O IFMPDNRWZZEZSL-SRVKXCTJSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- YJNDFEWPGLNLNH-IHRRRGAJSA-N Met-Tyr-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CS)C(O)=O)CC1=CC=C(O)C=C1 YJNDFEWPGLNLNH-IHRRRGAJSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- KQNDIKOYWZTZIX-FXQIFTODSA-N Ser-Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQNDIKOYWZTZIX-FXQIFTODSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- AZGZDDNKFFUDEH-QWRGUYRKSA-N Tyr-Gly-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AZGZDDNKFFUDEH-QWRGUYRKSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 230000008841 allosteric interaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000010256 bone deposition Effects 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000006328 chemical modification of amino acids Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 108010007375 seryl-seryl-seryl-arginine Proteins 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000010009 steroidogenesis Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Methods for increasing the level of free, biologically active proteins, including insulin-like growth factors, and for treating IGF-responsive conditions are provided. The methods generally comprise administering one or more ligand inhibitors that inhibit the binding of the protein to one or more insulin-like growth factor binding proteins. Suitable ligand inhibitors include analogs of IGF-I or IGF-II and small molecule inhibitors.
Description
CA 022248~9 1997-12-17 Wo 97139032 PCT/US97/06503 Description LIGAND INHIBITORS OF INSULIN-LIKE GROWTH FACTOR BINDlNG
PROTEINS AND METHODS OF USE THEREFOR
Technical Field The present invention relates generally to compositions and methods for the treatment of conditions responsive to the ~-lmini~tration of insulin, human growth 10 hormone, insulin-like growth factor, and/or other proteins that bind to insulin-like growth factor binding proteins. The invention is more particularly related to ligand inhibitors that inhibit the binding of insulin-like growth factor to insulin-like growth factor binding proteins, and to the use of such inhibitors for ~(lmini~tration (e.g., orally) to patients for the trç~tment of diabetes, neurodegenerative diseases and other disorders.
Back~round of the Invention Insulin-like growth factors (IGFs) are polypeptide hormones that are structurally similar to each other and to insulin. Two IGFs, known as IGF-I and IGF-II, have been identified. and both have a variety of metabolic actions and affect the growth 20 of multiple cell types (see, e.g.~ LeRoith and Roberts, "Insulin-like Growth Factors,' Ann. NYAcad Sci. 692:1-9, 1993). IGF-I is a 70 amino acid peptide with a molecular weight of 7649 and three disulfide bridges. Its actions in vivo include the mediation of growth hormone actions and bone deposition and maturation. IGF-I also mimics theaction of insulin, and the IGF-I receptor has high homology to the insulin receptor.
PROTEINS AND METHODS OF USE THEREFOR
Technical Field The present invention relates generally to compositions and methods for the treatment of conditions responsive to the ~-lmini~tration of insulin, human growth 10 hormone, insulin-like growth factor, and/or other proteins that bind to insulin-like growth factor binding proteins. The invention is more particularly related to ligand inhibitors that inhibit the binding of insulin-like growth factor to insulin-like growth factor binding proteins, and to the use of such inhibitors for ~(lmini~tration (e.g., orally) to patients for the trç~tment of diabetes, neurodegenerative diseases and other disorders.
Back~round of the Invention Insulin-like growth factors (IGFs) are polypeptide hormones that are structurally similar to each other and to insulin. Two IGFs, known as IGF-I and IGF-II, have been identified. and both have a variety of metabolic actions and affect the growth 20 of multiple cell types (see, e.g.~ LeRoith and Roberts, "Insulin-like Growth Factors,' Ann. NYAcad Sci. 692:1-9, 1993). IGF-I is a 70 amino acid peptide with a molecular weight of 7649 and three disulfide bridges. Its actions in vivo include the mediation of growth hormone actions and bone deposition and maturation. IGF-I also mimics theaction of insulin, and the IGF-I receptor has high homology to the insulin receptor.
2~ IGF-II is strongly homologous to IGF-I and this factor plays a role in, for example, bone remodeling and brain cell m~int-~n~nce and differentiation.
While IGF-I is present in a wide variety of body tissues, it is normally found in an inactive forrn in which it is bound to an IGF binding protein (IGFBP or BP). Six related BPs are known and have been designated IGFBP1-IGFBP6 (see, e.g., 30 Holly and Martin? "Insulin-like Growth Factor Binding Proteins: A Review of Methodological Aspects of Their Purification~ Analysis and Regulation~" G)owth CA 022248~9 1997-12-17 W O 97139032 PCTrUS97/06503 /
Regul. 4(Suppl 1):20-30, 1994; Langford et al., "The Insulin-like Growth Factor-I/Binding Protein Axis: Physiology, Phytophysiology and Therapeutic Manipulation,"
Eur. J. Clin. Invest. 23(9~:503-16, 1993). BPs play an important role in IGF regulation by exerting inhibitory and/or stim~ tory effects on IGF action. For example, about 5 90% of circulating IGF-I is present in a trimolecular complex containing IGFBP-3 and acid labile subunit (ALS). The IGF-I within such complexes is unable to bind to surface receptors, and is therefore biologically inactive. IGF-I present within the trimolecular complex also has a substantially longer half-life than uncomplexed IGF-I.
Attempts have been made to treat a wide variety of diseases by 10 ~flministration of IGF-I, IGF-II or an IGF binding protein. For example, the use of IGF-I for the treatment of cardiac disorders, intestinal disorders and osteoporosis are described in U.S. Patent ~o. 5,126,324, WO 91/12018 and European Patent Application 560,723, respectively, and the use of IGF-I for enhancing growth is described in U.S. Patent No. 5,126,324. IGF-I has also been studied for use in treating 15 insulin-resistant states and diabetes (see, e.g, Clemmons and Underwood, "Uses of Human lnsulin-Like Growth ~actor-I in Clinical Conditions,".J. Cli~ Endocrinol.
Metab. 79(1):4-6, 1994; Langford et al., "The Insulin-like Growth Factor-l/Binding Protein Axis: Physiology, Phytophysiology and Therapeutic Manipulation," E~r. J.Clin.Invest. 23(9):503-16,1993). Therapiesinvolvingthe~lminictrationofantibodies20 raised against IGF-I and specific binding proteins are described, for example, in WO
94/04569 and WO 92/14834, respectively.
Like treatment with insulin or growth hormone, however, treatment with intravenous IGF or antibodies thereto generally requires repeated intravenous injection, resulting in a high cost and practical difficulties for patients. Such treatments can also ~5 induce side effects due, for example, to the inahility to target specific tissues within the body. Further, the scope of treatment is limited to the tissues that may be reached by intravenous hormone ~ministration.
Accordingly, there is a need in the art for improved efficiency and control in treating conditions responsive to IGF and/or other proteins that bind to 30 insulin-like growth factor binding proteins. The present invention fulfills these needs and further provides other related advantages.
CA 022248~9 1997-12-17 Wo 9713go32 PCTrUSg7/06~03 Summary of the Invention Briefly stated, the present invention provides therapeutic and screening methods employing ligand inhibitors that inhibit the binding of proteins such as insulin-like growth factors to insulin-like growth factor binding proteins. In one aspect, the present invention provides a method for increasing the level of free, biologically active insulin-like growth factor in a patient, comprising ~riministering to a patient one or more ligand inhibitors that inhibit the binding of an insulin-like growth factor to one or more insulin-like growth factor binding proteins, and thereby increasing the level of free~ biologically ~ctive insulin-like growth factors within the patient.
ln a related aspect, methods are provided for treating an IGF-responsive condition in a patient, comprising ~mini.stering to a patient one or more ligandinhibitors that inhibit the binding of an insulin-like growth factor to one or more insulin-like growth factor binding proteins, and thereby alleviating an IGF-responsive condition in a patient.
In another aspect, the present invention provides a pharmaceutical composition comprising: (a) one or more ligand inhibitors that inhibit the binding of an insulin-like growth factor to one or more insulin-like growth factor binding proteins;
and (b) a physiologically acceptable carrier.
In yet another aspect, the present invention provides a method for screening for a small molecule inhibitor that inhibits binding of an insulin-like growth factor to an insulin-like growth factor binding protein, comprising: (a) combining an insulin-like growth factor with an insulin-like growth factor binding protein in a solution cont~ining a candidate small molecule, such that the binding protein and the growth factor are capable of forming a complex; and (b) determining the amount of complex in the solution, relative to a predetermined level of binding in the absence of the small molecule, and therefrom evaluating the ability of the small molecule to inhibit binding of an insulin-like growth factor to an insulin-like growth factor binding protein.
In still another aspect, methods are provided for increasing the level of a free protein in a patient, comprising a~mini.stering to a patient one or more ligand CA 022248~9 1997-12-17 inhibitors that inhibit the binding of a protein to one or more insulin-like growth factor binding proteins, and thereby increasing the level of the free protein within the patient.
These and other aspects of the present invention will become al,pale-lL
upon reference to the following detailed description and attached drawings. All 5 references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.
Brief Description of the Drawings Figure 1 is a graph that depicts the relative amount of binding, expressed 10 as cpm, of l25I-labeled IGF-I tracer to IGFBP-3, in the presence of varying amounts of [T59]hIGF-I, hIGF-I and [L24,59,60,A31~hIGF-I.
Figure 2 is a graph that presents the relative amount of DNA synthesis, expressed as cpm of incorporated [3H]-thymidine, of 3T3 cells in the presence ofvarying amounts of [T59]hIGF-I and [L24,59,60,A3 l]hIGF-I.
Figure 3 is a graph that depicts the relative amount of DNA synthesis, expressed as cpm of incorporated [3H]-thymidine, of 3T3 cells in the presence ofmedium only (column 1), 10 nM [T59]hIGF-I (column 2) and 10 nM [T59]hIGF-I plus 25 nM IGFBP-3 (column 3). The figure also shows the relative amount of DNA
synthesis in the presence of 10 nM [TS9]hIGF-I plus 25 nM IGFBP-3, with the addition 20 of varying amounts of [L24,59,60,A3 1 ]hIGF-I.
Figure 4 is a graph that shows the decrease in blood glucose levels (in mg/dl) over time (expressed in minutes) following ~lministration of [L24,59,60,A3 1 ]hIGF-I to diabetic NOD mice.
Figure 5 is a pair of graphs that depict the effect of insulin and 25 IGFBP3-LI ([L24,59,60,A31~hIGF-I) on plasma glucose in rats treated systemically with glucose.
Detailed Description of the Invention As noted above, the present invention is generally directed to methods 30 employing ligand inhibitors for increasing the level of a free protein, such as biologically active IGF, in one or more tissues within a patient. The proteins affected CA 022248~9 1997-12-17 W 097/39032 PCT~US97106503 by ligand inhibitors as described herein are generally proteins that bind to one or more IGF binding proteins. Increasing the level of such a protein within a patient may generally be useful in the treatment of a variety of conditions. Within the context of the present invention, "IGF" refers to one or more insulin-like growth factors (i.e., IGF-I
5 and/or IGF-II). IGFs are peptide hormones, and the sequences of IGF-I and IGF-II in humans and other species have been determined. Human IGF-I (hIGF-I) is a 70 amino acid peptide which has the sequence shown in Figure 1 (SEQ ID NO:l). "Free"
protein, such as IGF, refers to protein that is not complexed or bound to an IGF binding protein.
An "IGF binding protein" (IGFBP or BP) is any protein that binds to IGF-I and/or IGF-II in vivo, resulting in the inhibition of IGF binding to one or more cell surface receptors, or soluble forms thereof. A BP binds to IGF (i.e., forms a complex) through noncovalent interactions. IGF binding proteins contemplated within the context of the present invention include IGFBP-l, -2, -3, -4, -5 and -6. In particular, IGFBP-3, the most abundant binding protein in adult serum, has a high affinity for both IGF-I and IGF-II. Binding to IGFBP-3 increases the half life of IGF-I from about 10 minutes to approximately 15 hours (see Langford and Miell, ~20. J. Clin. Invest.23:503-526, 1993), and is therefore important for controlling the level of IGF-I in the circulation.
A '~ligand inhibitor," within the context of the present invention, is any molecule (other than an antibody to IGF-I or IGF-II) that is capable of inhibiting the binding of one or more proteins, especially IGF-I and/or IGF-II, to one or more IGFBPs. Due to the similarity between the structures of IGF-I and IGF-II, it will be apparent that many ligand inhibitors will inhibit the binding of both IGF-I and IGF-II to an IGFBP. In some cases, the binding of one IGF will be inhibited to a greater extent than that of the other IGF. In other cases, however, a ligand inhibitor may be specific for IGF-I or IGF-II. A ligand inhibitor may displace IGF from a complex with a BP?
thereby causing bound IGF to become free IGF. Such displacement may be reversible or irreversible. A ligand inhibitor may also block the binding of free IGF to a BP
because of a high affinity for either IGF or one or more BPs. For example, a ligand inhibitor may bind to IGF within a BP binding site, or may bind to a BP at an IGF
CA 022248~9 1997-12-17 Wo 97/39032 PCT/US97/06503 binding site. Alternatively, a ligand inhibitor may bind to IGF or a BP at a site that is not such a binding site, and inhibit complex formation through an allosteric interaction.
A ligand inhibitor having a lower affinity for IGF or one or more BPs may also inhibit the binding of free IGF to a BP when present at high enough concentrations. Similar 5 mech~nism.~ of inhibition may also be observed for ligand inhibitors directed against other proteins that bind to a BP.
As used herein, a molecule "inhibits" binding of a protein to an IGFBP
if the level of free protein increases by about 10-30% or more. An increase in the level of free protein may generally be detected using a variety of assays known to those of 10 ordinary skill in the art, such as im~ging, radioimmunoassays and precipitation techniques as described herein. One such assay is described in Example 1, below.Preferably, the characteristics of the ligand inhibitor are such that it has a 100 fold selectivity to the IGFBP (Kj < 10 nM).
Ligand inhibitors include, but are not limited to, analogs of IGF-I or 15 IGF-II and small molecule inhibitors. An IGF "analog" is a peptide that has an amino acid sequence that is substantially identical to a native IGF sequence, but that has one or more amino acid substitutions and/or modifications. Such substitutions and/ormodifications may reduce the biological activity of the peptide (i.e., decrease the affinity of the peptide for one or more cell surface receptors) without decreasing the 20 ability of the peptide to bind to one or more BPs. A "small molecule inhibitor" is a ligand inhibitor that is a natural or synthesized non-peptide, organic molecule. Small molecule inhibitors are typically identifled by screening libraries obtained from soil samples, plant extracts, marine microorg~ni~m~, fermentation broth, fungal broth, pharmaceutical chemical libraries, combinatorial libraries (both chemical and 25 biological) and the like. Such libraries may be obtained from a variety of sources, both commercial and proprietary.
One preferred ligand inhibitor of the present invention is the [L24,A3 1 ,L59,L60] analog of hIGF-I. This analog (which has the sequence recited in SEQ ID NO:2) binds to IGFBP-3, but not to the IGF-I cell surface receptor.
30 [L24,A31,L59,L60]hIGF-I may generally be prepared by techniques well known to those of ordinary skill in the art, such as by chemical synthesis.
CA 022248~9 1997-12-17 It will be a,~,pa~ t to those of ordinary skill in the art that modifications may be made to the sequence of [L24,A3 1 ,L59,L60]hIGF-I such that the ability of the analog to inhibit the binding of IGF-I to IGFBP-3 is retained. Such variants are within the scope of the present invention, and may generally be identified by modifying the 5 sequence and evaluating the inhibitory plo~ lies of the analog as described below.
Preferably, a variant contains conservative substitutions, (i.e., one in which an amino acid is substituted for another amino acid that has simi}ar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure andhy-llvlJ~Lllic nature of the polypeptide to be substantially unchanged). Amino acids 10 suitable for conservative substitutions include those having functionally similar side chains. For example, a hydrophobic residue (e.g., glycine, alanine, valine, leucine, isoleucine and methionine) may replace another such residue. Similarly, conservative substitutions may involve interch~nging hydrophilic residues (e.g, arginine and Iysine, glutamine and asparagine, threonine and serine), basic residues (e.g, lysine, arginine 15 and histidine), and/or acidic residues (e.g., aspartic acid and glutamic acid). Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids, or the chemical modification of amino acids, that have minim~l influence on the inhibitory properties of the analog.
Small molecule inhibitors according to the present invention may be 20 prepared using methods well known to those of ordinary skill in the art. According to a preferred method, a chemical library of small molecules as described above may be screened using a binding assay designed to detect molecules that displace a protein such as IGF from a binding protein. For example, a complex of radiolabeled IGF-I and a binding protein (such as BP-3) may be incubated in the presence of a candidate small 25 molecule. Complexes (i.e., noncovalent associations of IGF and binding protein) may then be separated from the rem~in-ler of the solution using, for example, polyethylene glycol precipitation. Those small molecules that bind to the complex and displace the growth fàctor from the binding protein may then be detected by a decrease in theamount of radiolabel precipitated. Those of ordinary skill in the art will recognize that 30 a variety of other assay formats may be employed in such a screen, including two-site sandwich ELISAs, chemiluminescent assays and fluorescent assays.
.. .
CA 022248~9 1997-12-17 W O 97~9032 PCT~US97/06503 IGF-I, IGF-II and binding proteins for use in such assays may generally be prepared by techniques known to those of ~rdill~ y skill in the art, such as those provided in Rechler, ~itamins and Hormones 4'7:1-114, 1993, and references citedtherein. Appropriate techniques include chemical synthesis (described, for example, in 5 Shim~ki et al., J. Biol. C~em. 266:10646-10653, 1991), purification from an aE~I,ropliate biological sample (described, for example, in Shimonaka et al., Biochem.
~iophys. Res. Comm. 165:189-195, 1989) and expression in a suitable host, such as yeast(described, for exarnple, in Bayne et al., ~ Biol. C~em. 265: 15648- 15652, 1990).
In this regard, the IGF and binding proteins employed may be the native proteins, or 10 may contain modifications, such as the addition of label or the addition or deletion of sequences that have minim~l effect on the binding properties of the protein. Antibodies suitable for use in ELISA assays are commercially available from, for example? Amano Pharmaceutical Co. or may be raised against the IGF and/or binding protein of interest by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., 15 Harlow and Lane, Antibodies. A l aboratory Man2~al, Cold Spring Harbor Laboratory, 1988. Monoclonal antibodies may be plepared, for example, using the technique ofKohler and Milstein, Eur. J. Immunol. 6:511 -519, 1976, and improvements thereto.
A secondary bioassay, based on the activity of the binding protein of interest, may also be employed for further characterization of a small molecule inhibitor 20 or other ligand inhibitor. For example, IGF-I stimulates 3T3 fibroblast proliferation in vi~ro. The addition of a binding protein inhibits this stimulation, and the level of inhibition can be deterrnined using [3H]thymidine incorporation assays well known to those of ordinary skill in the art. Molecules that are capable of reversing the binding protein inhibition are ligand inhibitors. Similar assays may be designed for use with 25 specific binding proteins based on the known biological properties of the binding proteins (e.g., the inhibition of granulosa cell steroidogenesis as described in Bicsak et al., Endocrinol. 126:2184-2189, 1990).
Animal models may be useful for further characterization of ligand inhibitors. For example, the effect of a ligand inhibitor on blood glucose levels may be 30 evaluated using ~nim~ such as rats. An inhibitor that normalizes blood glucose levels in hyperglycemic or diabetic animals may be useful for the treatment of diabetes.
CA 022248~9 1997-12-17 W O 97/39032 PCTrUS97/06503 Similarly, growth hormone deficient ~nim~l~ may be used to evaluate the utility of a ligand inhibitor for the treatment of conditions that respond to the ~fimini.~tration of ~ human growth horrnone, such as human growth hormone resistance.
Ligand inhibitors of the present invention may generally be used to 5 increase the level of free, biologically active IGF in a patient and to treat any of a variety of IGF-responsive conditions. The term "IGF-responsive condition"
encomr~ses any condition of a patient that may be alleviated or treated by the ~,lmini.stration of IGF, and includes diseases such as diabetes (insulin dependent, non-insulin dependent and type I/II), growth retardation, osteoporosis, human growth10 horrnone resistance, ALS, demyelinating diseases (including via remyelination), multiple sclerosis, muscular dystrophy, stroke, ophthalmic conditions, infertility, Alzheimer's disease and other dementias. The terrn "IGF-responsive condition" also encomp~cses states in which it is desirable to induce wound healing or bone repair, such as bone remodeling. As used herein, a "patient" refers to any warm-blooded 15 animal, preferably a human. A patient may or may not be afflicted with an IGF-responsive condition. Patients that are so afflicted may generally be identified through clinical diagnosis according to methods that are well known to those of ordinary skill in the art.
Within the context of the present invention, the minimum acceptable 20 increase in the level of free IGF is 10%, a preferred level is at least 50% and a particularly preferred level is at least ~0%. The level of free IGF may generally be determined by methods known in the art, such as resolving the plasma sample to different molecular size fractions on a Sephadex G-50 fine column developed in 0.02M
potassium phosphate buffer, pH 7.2. The free IGF-I with a molecular weight of 7.6 25 kDa will elute later than the larger molecular weight IGF-IIIGFBP complex. The free IGF-I fraction can then be quantitated by radioimmunoassay. Alternatively, bloodglucose levels may be used as an indirect measurement of free IGF levels.
Other techniques, such as MRI, PETSCAN, spect~c~nning or other similar im~ging techniques, may also be employed to measure the increase in the level 30 of free IGF. Some of these techniques use radiolabeled ligand to IGF binding proteins or IGF receptors. A preferred method is image analysis using PET positron-emitting CA 022248~9 1997-12-17 wO 97/39032 PCT/US97/06503 ligands (e.g., "C or '8F) of a single photon-emitting ligand (e.g, l23I-labeled ligand to IGF-binding proteins or IGF receptors). Free IGF levels are correlated to the amount of binding of the radiolabeled ligand. An increase in IGF levels is manifested by adecreased binding of the radiolabeled ligand to the IGF-binding proteins and IGF5 receptors. Within this im~ging technique, an increase in free IGF levels of about 10-30% or more is sufficient.
For ~-lmini~ration to a patient, the ligand inhibitors are preferably incorporated into pharmaceutical compositions, which comprise a therapeutically effective amount of one or more ligand inhibitors and a physiologically acceptable 10 carrier. A "physiologically acceptable carrier" may be any composition, carrier or diluent that is capable of aAmini~tration to a m~mm~l without producing undesirable physiological effects, such as nausea, dizziness or gastric upset. While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending 15 on the mode of allministration. In general, the pharmaceutical compositions may be ~lmini.~tered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g, by aspiration) or orally. For parenteral a~lmini.~tration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax and/or a buffer. For oral ~lmini.ctration, any of the above carriers and/or a 20 solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed.
Small molecule inhibitors of the present invention are preferably capable of oral atlmini.stration in, for example, capsule or tablet form. Such ligand inhibitors have the advantage of decreased cost and increased convenience, as compared to 25 conventional treatments that rely on repeated intravenous injection. In general, the ability of a small molecule inhibitor to be a~mini~tered orally may be determined by in vivo assays. Such assays typically measure the decrease in the level of IGF bound to binding proteins in response to oral ~flmini~tration of the small molecule inhibitor. For example, the amount of small molecule inhibitor in the blood may be measured based 30 on its ability to inhibit binding of '25I-hlGF-I to IGF binding proteins. Blood samples may be drawn at various times after a~lmini.~tration of small molecule inhibitor or CA 022248~9 1997-12-17 W O 97139032 PCT~US97/06503 vehicle to ~nim~l~ or humans. If necessary, the ligand inhibitor may be extracted from the blood by standard procedures (e.g., ~0% acetonitrile/0.1% trifluoroacetic acid).
Briefly, 1 mL of the extraction solvent may be added to 200 IlL of plasma and the mixture is vortexed. The resultant precipitate may then be centrifuged at 12,000 x g for 5 5 minutes. The supernatant cont~ining the ligand inhibitor may then be Iyophilized and reconstituted in assay buffer (PBS cont~ining 0.2% Nonidet p 40TM) to yield a reconstituted extract. Blood samples or reconstituted extracts may then be used in a binding assay, such as that described in Example l, below. Ligand inhibitors capable of oral ~lm;ni~tration will show inhibition of binding of '25I-hIGF-I to IGF binding 10 proteins, relative to the vehicle control.
Routes and fre4uency of ~(lministration, as well as dosage, will vary depending on the ligand inhibitor and the desired in vivo response. A suitable dose is an amount of ligand inhibitor that, when a~1mini~tered as described above, is capable of improving the clinical outcome for a patient (e.g, fewer hypoglycemic episodes for 15 diabetic patients) in treated patients as compared to untreated patients.. ln general, for pharmaceutical compositions comprising one or more ligand inhibitors, the amount of each ligand inhibitor present in a dose ranges from about 0.1 to about 10, preferably from about 1 to about 3 mg/kg. A larger or smaller amount may, however, be employed, depending on the size of the ligand inhibitor. Treatments are typically 20 conducted one-two times per day, and may need to be continuous for retention of benefit. Patients may be monitored by assessing IGF levels as described above and by evaluating clinical symptoms.
A significant advantage of the present invention lies in the ability to vary the potency of the ph~rm~r.eutical composition and to target IGF effects to specific 25 tissues, minimi7ing side effects. The potency may be varied through the use of ligand inhibitors with varying abilities to inhibit the binding of IGF to one or more binding proteins. In this regard, the relative abilities of ligand inhibitors to inhibit binding may be evaluated by, for example, comparing the amount of inhibitor needed for half maximal displacement of specific binding in all in vitro binding assay as described 30 herein.
CA 022248~9 l997-l2-l7 W O 97139032 PCTfUS97/06503 IGF effects may be targeted by using ligand inhibitors that are specific for one or more particular binding proteins, and exploiting the relative tissue specificity of each of the six known binding proteins (see Rech}er, Vi~am~ns and Hormones 47:1-114, 1993). Binding protein-specific ligand inhibitors may be developed, as noted 5 above, by using different binding proteins within the binding assay described herein for the identification of small molecule inhibitors. Administration of such ligand inhibitors results in the release of IGF in only those tissues that contain the targeted binding proteins. For example, IGFBP-2, -4 and -6 are more prevalent in the brain. In addition, IGFBP-1 is present in the brain, although at lower concentrations. Small molecule 10 inhibitors that are specific for these binding proteins and are capable of crossing the blood/brain barrier (as discussed below) will release IGF in the brain, while leaving most of the serum IGF in its inactive form. Such inhibitors may be particularly useful for the treatment of ALS and other neurodegenerative diseases such as multiple sclerosis, demyelin~ting disease and Alzheimer's disease. Alternatively, peripheral 15 effects may be manipulated using primarily IGFBP-I, -3, -4, and -5. As noted above, circulating IGF-I may be released by inhibiting binding to IGFBP-3. In this regard, small molecule inhibitors that are not capable of crossing the blood/brain barrier are particularly well suited for providing peripheral effects.
The amount of a small molecule inhibitor that crosses the bloodlbrain 20 barrier may be assessed by techniques known to those of ordinary skill in the art, such as MRI, PETSCAN, spect~c~nnin~ or other similar im~gin~ techniques, some of which use radiolabeled ligand to IGF binding proteins or IGF receptors. As noted above, a preferred method is image analysis using PET positron-emitting ligands (e.g., "C or l8F) of a single photon-emitting ligand (e.g., '23I-labeled ligand to IGF-binding proteins 25 or IGF receptors). Decreased binding of the radiolabeled ligand to the IGF-binding proteins and IGF receptors indicates an increase in IGF levels. Such decreased binding is indicative of the level of small molecule inhibitor that has crossed the blood/brain barrier. Alternatively, IGF-I levels in the cerebrospinal fluid (CSF) can be measured by radioimmunoassay using commercially available assay kits (e.g, Peninsula 30 Laboratories, Inc., Belmont, CA) or by polyethylene/glycol precipitation, as described CA 022248~9 l997-l2-l7 in Example 1. An increase in the level of IGF-I in the CSF is indicative of an increase in the level of IGF-I in the brain.
In ~nim~l~, the blood/brain penetration of the small molecule inhibitors can be tested by ex vivo binding. Briefly, ~nim~ls may be injected (intravenously or 5 orally) with 15-50 mg/kg of a small molecule ligand inhibitor. The ~nim~l~ are then sacrif1ced at 15, 30, 60 and 90 minutes after ~-lmini.~tration of the drug. The brains are removed and homogenized in solubilization buffer (PBS cont~ining 0.2% Nonidet p 40TM detergent). The assay is then carried out by polyethyleneglycol pleci,oil~tion of the bound '2sI-hIGF/hIGFBP-3 complex. If any dru-g is present in the brain, it will 10 inhibit binding of the '25I-hIGF-I to the IGF binding proteins? resulting in fewer precipitated counts in the drug-treated animals than in :~nimz~ treated with vehicle alone.
Those of ordinary skill in the art will recognize that other tissues, and thus other IGF responsive conditions, may be targeted by ~-lmini~tering ligand 15 inhibitors specific for other binding proteins, or combinations thereof. The tissue distribution of the six known IGF binding proteins is presented in Table I, below:
Table I
Primary Tissue Distribution of IGF Bindin~ Proteins IGF Binding Protein Tissues BP- I placenta, liver BP-2 CSF, CNS, liver BP-3 ovary, adrenal, heart, kidney, liver, stomach, intestine BP-4 liver, brain cortex BP-5 liver, brain, lung, heart, spleen, stomach, kidney, adrenal, intestine BP-6 CSF and all tissue The following Examples are offered by way of illustration and not by way of limitation.
CA 022248~9 1997-12-17 W O 97139032 PCT~US97/06503 EXAMPLES
Example 1 5 Inhibition of IGF/BP-3 Bindin~ Usin~ hIGF-I Analo~s This Example illustrates the in vitro and in vivo inhibition of binding of IGF-I to BP-3, resulting in increased levels of free, biologically active IGF-I.
10 A. In vitro Bindin~ Assay The binding assay was performed in duplicate at room temperature in 0.2% BSA-PBS, pH 7.2. BP-3 was purified from rat serum as described in Shimonakaet al., ~iochem. Biophys. Res. Comm. 165:189-195, 1989. Two hundred microliters of a 2.5 nM BP-3 solution (0.5 pmol) was added to a 12 x 75-mm glass tube. The reaction 15 was started by the addition of an increasing concentration of unlabeled [T59]hIGF-I or [L24,S9,60,A31]hIGF-I (both prepared by chemical synthesis according to the procedure described in Shim~ki et al., J. Biol. Chem. 266:10646-10653, 1991) in 100 ~L followed by 100 ~L of '25I-labeled [T59]hIGF-I (30,000 cpm/~0.3 ng). After incubation for 2.5 hours, 100 ~L of 20% BSA and 500 IlL of 20% PEG-8000 in 20 phosphate buffered saline (PBS) was added and the mixture was vortexed and then centrifuged for 30 minutes at 3500 rpm. The supernatant was carefully removed bysuction and the pellet counted in a gamma counter.
As shown in Figure 1, 0.5 pmol of IGFBP-3 could bind 23.3% of the '2sI-labeled IGF-I tracer, and the non-specific binding was 1.8%. Half-maximal 25 displacement of the specific binding was achieved at approximately 0.32 pmol [T59~hIGF-I per tube and 0.8 pmol ~L24,59,60,A31]hlGF-I per tube (Figure 1).
This assay may also be employed to screen for small molecule ligand inhibitors.
CA 022248~9 1997-12-17 W O 97/39032 PCTrUS97/06S03 B. r3Hl-ThYmidine Incorporation Assay BALB/c 3T3 cells were trypsanized and diluted to 50,000 cells per mL
in 10% calf serum-DMEM. The cells were aliquoted to 96-well microtiter plates (180 ~L/well). After 48 hours incubation at 37~C and 5% CO2, the plates were washed twice S with 0.1% calf serum-DMEM and incubated for an additional 24 hours. To each well, 20 ~L of sample(s) cont~ining IGF analog and/or binding protein and I ~LCi [3H]-thymidine were added and the plates were incubated for precisely 24 hours. After the incubation, the medium was removed and the cells were fixed by adding 200 IlL of25% acetic acid-75% ethanol per well. After removal of the fixing solution the plates 10 were washed three times with cold 10% TCA and the cells in each well were lysed in 200 ~L 0.2M NaOH. The entire 200 IlL of lysed solution was transferred into a scintillation vial and 2.5 mL scintillation liquid was added and the vials counted in a ,~-counter.
[T59]hIGF-I dose dependently stimulated proliferation, as measured by 15 DNA synthesis, in 3T3 cells with a ED~o of 10-20 nM (Figure 2), whereas [L24,59,60,A31]hIGF-I did not induce any DNA synthesis in 3T3 cells with a dose as high as 8,000 nM (Figure 2). After incubation with 10 nM [T59]hIGF-I, the incorporated [3H]-thymidine in the 3T3 cells was increased 4-fold in comparison with the control (Figure 3). Incubation with 25 nM IGFBP-3 completely inhibited the [3H]-20 thymidine incorporation induced by 10 nM [T59]hIGF-I ~Figure 3~. Addition of [L24,59,60,A31]hIGF-I (which only binds to IGFBP-3, and not to the IGF-I receptors) could totally reverse the blocking effect of 25 nM IGFBP-3 to release the [T59~hIGF-I
bioactivity with a EDso of about 25 nM [L24,59,60,A31]hIGF-I (Figure 3).
This assay may also be employed to evaluate the biological activity of 25 small molecule ligand inhibitors.
CA 022248~9 1997-12-17 W O 97/39032 PCT~US97/06503 Example 2 Norm~1i7~tion of Blood Glucose Levels in Hyper~lvcemic Rats usin~ IGFBP-3 Inhibitor This Exarnple illustrates the use of ligand inhibitors of IGFBP-3 for the treatment of ~nim~ with elevated blood glucose.
Rats were made hyperglycemic with an intraperitoneal injection of glucose. The ~L24,59,60,A31]hIGF-I analog (noted as IGFBP3-LI) (S~lg/min) was infused intravenously for 40 minutes and blood glucose levels were monitored before, 10 during and after the infusion. As a control, bovine insulin was infused at 1 ~Lg/min for 40 minutes and blood glucose was monitored at the sarne time points.
As depicted in Figure 5, while the insulin dramatically lowered blood glucose levels below the normal baseline, making the Anim~ hypoglycemic, the [L24,59,60,A31]hIGF-I analog surprisingly normalized blood glucose levels. In a 15 related experiment, insulin dramatically decreased blood glucose levels on a normal fasted blood glucose baseline, but [L24,59,60,A31]hIGF-I had no effect.
These results indicate that [L24,59,60,A31]hIGF-I can normalize blood glucose levels in animals with elevated blood glucose but, unlike insulin, this analog does not decrease the blood glucose levels below the normal baseline and make the 20 ~nimz~ hypoglycemic. Thus, the use of inhibitors of IGF binding to IGFBP-3 have distinct advantages over insulin for the treatment of diabetes. Diabetics receiving insulin normally experience a rebound effect after intravenous insulin injection such that blood sugar levels fall below normal levels. The inhibitors of the present invention normalize blood sugar levels without the risk of hypoglycemia. In addition, both25 insulin dependent and non-insulin dependent diabetics may be treated.
CA 022248~9 1997-12-17 W 097/39032 PCTfUS97106S03 ExamPle 3 Norm~li7~tion of Blood Glucose Levels in Diabetic Mice using IGFBP-3 Inhibitor S This Example illustrates the use of ligand inhibitors of IGFBP-3 for the treatment of diabetes in ~nim~
Two severely diabetic female NOD mice with blood glucose levels of 450-500 mg/dl were treated with the [L24,59,60,A31]hIGF-I analog. These mice were severely diabetic and were expected to die within two days without treatment. The 10 [L24,59,60,A31]hlGF-I analog was a~mini.~tered at time 0 (25 ~Lg/animal). at 30 minutes (50 ~Lg/animal) and at 60 min (100 ~lg/animal) by tail vein injection inphysiological saline). Blood glucose levels were monitored using a glucometer before the initial injection and throughout the time course of the experiment.
In both ~nim~l~, the blood glucose levels decreased dramatically to 250 15 mg/dl after 80 minutes (Figure 4). Since the threshold for normal blood glucose is 220 mg/dl, the blood glucose levels were almost normalized in both ~nim711~. These results demonstrate that the [L24,59,60,A31]hIGF-I analog may be used to lower blood glucose levels in the treatment of diabetes.
From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the purpose of illustration, various modifications may be made without deviating from the spirit and scope of the invention.
CA 022248~9 1997-12-17 W O 97/39032 PCTrUS97106503 SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANTS: DOMINIC P. BEHAN, NICHOLAS LING, XIN-JUN LIU AND
AMITABH GAUR
(ii) TITLE OF INVENTION: LIGAND INHIBITORS OF INSULIN-LIKE GROWTH
FACTOR BINDING PROTEINS AND METHODS OF USE THEREFOR
(iii) NUMBER OF SEQUENCES: 2 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: SEED and BERRY LLP
(B) STREET: 6300 Colu~bia Center. 701 Fifth Avenue (C) CITY: Seattle (D) STATE: Washington (E) COUNTRY: USA
(F) ZIP: 98104-7092 (v) COMPUTER READABLE FORM.
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA:
(A) APPLICATTON NUMBER:
(B) FILING DATE: 17-APR-1996 (C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Maki, David J.
(B) REGISTRATION NUMBER: 31,392 (C) REFERENCE/DOCKET NUMBER: 690068.425 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (206) 622-4900 (B) TELEFAX: (206) 682-6031 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
CA 022248~9 1997-12-17 W 097/39032 PCT~US97/06503 (A) LENGTH: 70 amino acids (B) TYPE: amino acid (C~ STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu Lys Pro Ala Lys Ser Ala (2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 70 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe Val Cys Gly Asp Arg Gly Phe Leu Phe Asn Lys Pro Thr Gly Ala Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Leu Leu Cys Ala Pro Leu Lys Pro Ala Lys Ser Ala
While IGF-I is present in a wide variety of body tissues, it is normally found in an inactive forrn in which it is bound to an IGF binding protein (IGFBP or BP). Six related BPs are known and have been designated IGFBP1-IGFBP6 (see, e.g., 30 Holly and Martin? "Insulin-like Growth Factor Binding Proteins: A Review of Methodological Aspects of Their Purification~ Analysis and Regulation~" G)owth CA 022248~9 1997-12-17 W O 97139032 PCTrUS97/06503 /
Regul. 4(Suppl 1):20-30, 1994; Langford et al., "The Insulin-like Growth Factor-I/Binding Protein Axis: Physiology, Phytophysiology and Therapeutic Manipulation,"
Eur. J. Clin. Invest. 23(9~:503-16, 1993). BPs play an important role in IGF regulation by exerting inhibitory and/or stim~ tory effects on IGF action. For example, about 5 90% of circulating IGF-I is present in a trimolecular complex containing IGFBP-3 and acid labile subunit (ALS). The IGF-I within such complexes is unable to bind to surface receptors, and is therefore biologically inactive. IGF-I present within the trimolecular complex also has a substantially longer half-life than uncomplexed IGF-I.
Attempts have been made to treat a wide variety of diseases by 10 ~flministration of IGF-I, IGF-II or an IGF binding protein. For example, the use of IGF-I for the treatment of cardiac disorders, intestinal disorders and osteoporosis are described in U.S. Patent ~o. 5,126,324, WO 91/12018 and European Patent Application 560,723, respectively, and the use of IGF-I for enhancing growth is described in U.S. Patent No. 5,126,324. IGF-I has also been studied for use in treating 15 insulin-resistant states and diabetes (see, e.g, Clemmons and Underwood, "Uses of Human lnsulin-Like Growth ~actor-I in Clinical Conditions,".J. Cli~ Endocrinol.
Metab. 79(1):4-6, 1994; Langford et al., "The Insulin-like Growth Factor-l/Binding Protein Axis: Physiology, Phytophysiology and Therapeutic Manipulation," E~r. J.Clin.Invest. 23(9):503-16,1993). Therapiesinvolvingthe~lminictrationofantibodies20 raised against IGF-I and specific binding proteins are described, for example, in WO
94/04569 and WO 92/14834, respectively.
Like treatment with insulin or growth hormone, however, treatment with intravenous IGF or antibodies thereto generally requires repeated intravenous injection, resulting in a high cost and practical difficulties for patients. Such treatments can also ~5 induce side effects due, for example, to the inahility to target specific tissues within the body. Further, the scope of treatment is limited to the tissues that may be reached by intravenous hormone ~ministration.
Accordingly, there is a need in the art for improved efficiency and control in treating conditions responsive to IGF and/or other proteins that bind to 30 insulin-like growth factor binding proteins. The present invention fulfills these needs and further provides other related advantages.
CA 022248~9 1997-12-17 Wo 9713go32 PCTrUSg7/06~03 Summary of the Invention Briefly stated, the present invention provides therapeutic and screening methods employing ligand inhibitors that inhibit the binding of proteins such as insulin-like growth factors to insulin-like growth factor binding proteins. In one aspect, the present invention provides a method for increasing the level of free, biologically active insulin-like growth factor in a patient, comprising ~riministering to a patient one or more ligand inhibitors that inhibit the binding of an insulin-like growth factor to one or more insulin-like growth factor binding proteins, and thereby increasing the level of free~ biologically ~ctive insulin-like growth factors within the patient.
ln a related aspect, methods are provided for treating an IGF-responsive condition in a patient, comprising ~mini.stering to a patient one or more ligandinhibitors that inhibit the binding of an insulin-like growth factor to one or more insulin-like growth factor binding proteins, and thereby alleviating an IGF-responsive condition in a patient.
In another aspect, the present invention provides a pharmaceutical composition comprising: (a) one or more ligand inhibitors that inhibit the binding of an insulin-like growth factor to one or more insulin-like growth factor binding proteins;
and (b) a physiologically acceptable carrier.
In yet another aspect, the present invention provides a method for screening for a small molecule inhibitor that inhibits binding of an insulin-like growth factor to an insulin-like growth factor binding protein, comprising: (a) combining an insulin-like growth factor with an insulin-like growth factor binding protein in a solution cont~ining a candidate small molecule, such that the binding protein and the growth factor are capable of forming a complex; and (b) determining the amount of complex in the solution, relative to a predetermined level of binding in the absence of the small molecule, and therefrom evaluating the ability of the small molecule to inhibit binding of an insulin-like growth factor to an insulin-like growth factor binding protein.
In still another aspect, methods are provided for increasing the level of a free protein in a patient, comprising a~mini.stering to a patient one or more ligand CA 022248~9 1997-12-17 inhibitors that inhibit the binding of a protein to one or more insulin-like growth factor binding proteins, and thereby increasing the level of the free protein within the patient.
These and other aspects of the present invention will become al,pale-lL
upon reference to the following detailed description and attached drawings. All 5 references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.
Brief Description of the Drawings Figure 1 is a graph that depicts the relative amount of binding, expressed 10 as cpm, of l25I-labeled IGF-I tracer to IGFBP-3, in the presence of varying amounts of [T59]hIGF-I, hIGF-I and [L24,59,60,A31~hIGF-I.
Figure 2 is a graph that presents the relative amount of DNA synthesis, expressed as cpm of incorporated [3H]-thymidine, of 3T3 cells in the presence ofvarying amounts of [T59]hIGF-I and [L24,59,60,A3 l]hIGF-I.
Figure 3 is a graph that depicts the relative amount of DNA synthesis, expressed as cpm of incorporated [3H]-thymidine, of 3T3 cells in the presence ofmedium only (column 1), 10 nM [T59]hIGF-I (column 2) and 10 nM [T59]hIGF-I plus 25 nM IGFBP-3 (column 3). The figure also shows the relative amount of DNA
synthesis in the presence of 10 nM [TS9]hIGF-I plus 25 nM IGFBP-3, with the addition 20 of varying amounts of [L24,59,60,A3 1 ]hIGF-I.
Figure 4 is a graph that shows the decrease in blood glucose levels (in mg/dl) over time (expressed in minutes) following ~lministration of [L24,59,60,A3 1 ]hIGF-I to diabetic NOD mice.
Figure 5 is a pair of graphs that depict the effect of insulin and 25 IGFBP3-LI ([L24,59,60,A31~hIGF-I) on plasma glucose in rats treated systemically with glucose.
Detailed Description of the Invention As noted above, the present invention is generally directed to methods 30 employing ligand inhibitors for increasing the level of a free protein, such as biologically active IGF, in one or more tissues within a patient. The proteins affected CA 022248~9 1997-12-17 W 097/39032 PCT~US97106503 by ligand inhibitors as described herein are generally proteins that bind to one or more IGF binding proteins. Increasing the level of such a protein within a patient may generally be useful in the treatment of a variety of conditions. Within the context of the present invention, "IGF" refers to one or more insulin-like growth factors (i.e., IGF-I
5 and/or IGF-II). IGFs are peptide hormones, and the sequences of IGF-I and IGF-II in humans and other species have been determined. Human IGF-I (hIGF-I) is a 70 amino acid peptide which has the sequence shown in Figure 1 (SEQ ID NO:l). "Free"
protein, such as IGF, refers to protein that is not complexed or bound to an IGF binding protein.
An "IGF binding protein" (IGFBP or BP) is any protein that binds to IGF-I and/or IGF-II in vivo, resulting in the inhibition of IGF binding to one or more cell surface receptors, or soluble forms thereof. A BP binds to IGF (i.e., forms a complex) through noncovalent interactions. IGF binding proteins contemplated within the context of the present invention include IGFBP-l, -2, -3, -4, -5 and -6. In particular, IGFBP-3, the most abundant binding protein in adult serum, has a high affinity for both IGF-I and IGF-II. Binding to IGFBP-3 increases the half life of IGF-I from about 10 minutes to approximately 15 hours (see Langford and Miell, ~20. J. Clin. Invest.23:503-526, 1993), and is therefore important for controlling the level of IGF-I in the circulation.
A '~ligand inhibitor," within the context of the present invention, is any molecule (other than an antibody to IGF-I or IGF-II) that is capable of inhibiting the binding of one or more proteins, especially IGF-I and/or IGF-II, to one or more IGFBPs. Due to the similarity between the structures of IGF-I and IGF-II, it will be apparent that many ligand inhibitors will inhibit the binding of both IGF-I and IGF-II to an IGFBP. In some cases, the binding of one IGF will be inhibited to a greater extent than that of the other IGF. In other cases, however, a ligand inhibitor may be specific for IGF-I or IGF-II. A ligand inhibitor may displace IGF from a complex with a BP?
thereby causing bound IGF to become free IGF. Such displacement may be reversible or irreversible. A ligand inhibitor may also block the binding of free IGF to a BP
because of a high affinity for either IGF or one or more BPs. For example, a ligand inhibitor may bind to IGF within a BP binding site, or may bind to a BP at an IGF
CA 022248~9 1997-12-17 Wo 97/39032 PCT/US97/06503 binding site. Alternatively, a ligand inhibitor may bind to IGF or a BP at a site that is not such a binding site, and inhibit complex formation through an allosteric interaction.
A ligand inhibitor having a lower affinity for IGF or one or more BPs may also inhibit the binding of free IGF to a BP when present at high enough concentrations. Similar 5 mech~nism.~ of inhibition may also be observed for ligand inhibitors directed against other proteins that bind to a BP.
As used herein, a molecule "inhibits" binding of a protein to an IGFBP
if the level of free protein increases by about 10-30% or more. An increase in the level of free protein may generally be detected using a variety of assays known to those of 10 ordinary skill in the art, such as im~ging, radioimmunoassays and precipitation techniques as described herein. One such assay is described in Example 1, below.Preferably, the characteristics of the ligand inhibitor are such that it has a 100 fold selectivity to the IGFBP (Kj < 10 nM).
Ligand inhibitors include, but are not limited to, analogs of IGF-I or 15 IGF-II and small molecule inhibitors. An IGF "analog" is a peptide that has an amino acid sequence that is substantially identical to a native IGF sequence, but that has one or more amino acid substitutions and/or modifications. Such substitutions and/ormodifications may reduce the biological activity of the peptide (i.e., decrease the affinity of the peptide for one or more cell surface receptors) without decreasing the 20 ability of the peptide to bind to one or more BPs. A "small molecule inhibitor" is a ligand inhibitor that is a natural or synthesized non-peptide, organic molecule. Small molecule inhibitors are typically identifled by screening libraries obtained from soil samples, plant extracts, marine microorg~ni~m~, fermentation broth, fungal broth, pharmaceutical chemical libraries, combinatorial libraries (both chemical and 25 biological) and the like. Such libraries may be obtained from a variety of sources, both commercial and proprietary.
One preferred ligand inhibitor of the present invention is the [L24,A3 1 ,L59,L60] analog of hIGF-I. This analog (which has the sequence recited in SEQ ID NO:2) binds to IGFBP-3, but not to the IGF-I cell surface receptor.
30 [L24,A31,L59,L60]hIGF-I may generally be prepared by techniques well known to those of ordinary skill in the art, such as by chemical synthesis.
CA 022248~9 1997-12-17 It will be a,~,pa~ t to those of ordinary skill in the art that modifications may be made to the sequence of [L24,A3 1 ,L59,L60]hIGF-I such that the ability of the analog to inhibit the binding of IGF-I to IGFBP-3 is retained. Such variants are within the scope of the present invention, and may generally be identified by modifying the 5 sequence and evaluating the inhibitory plo~ lies of the analog as described below.
Preferably, a variant contains conservative substitutions, (i.e., one in which an amino acid is substituted for another amino acid that has simi}ar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure andhy-llvlJ~Lllic nature of the polypeptide to be substantially unchanged). Amino acids 10 suitable for conservative substitutions include those having functionally similar side chains. For example, a hydrophobic residue (e.g., glycine, alanine, valine, leucine, isoleucine and methionine) may replace another such residue. Similarly, conservative substitutions may involve interch~nging hydrophilic residues (e.g, arginine and Iysine, glutamine and asparagine, threonine and serine), basic residues (e.g, lysine, arginine 15 and histidine), and/or acidic residues (e.g., aspartic acid and glutamic acid). Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids, or the chemical modification of amino acids, that have minim~l influence on the inhibitory properties of the analog.
Small molecule inhibitors according to the present invention may be 20 prepared using methods well known to those of ordinary skill in the art. According to a preferred method, a chemical library of small molecules as described above may be screened using a binding assay designed to detect molecules that displace a protein such as IGF from a binding protein. For example, a complex of radiolabeled IGF-I and a binding protein (such as BP-3) may be incubated in the presence of a candidate small 25 molecule. Complexes (i.e., noncovalent associations of IGF and binding protein) may then be separated from the rem~in-ler of the solution using, for example, polyethylene glycol precipitation. Those small molecules that bind to the complex and displace the growth fàctor from the binding protein may then be detected by a decrease in theamount of radiolabel precipitated. Those of ordinary skill in the art will recognize that 30 a variety of other assay formats may be employed in such a screen, including two-site sandwich ELISAs, chemiluminescent assays and fluorescent assays.
.. .
CA 022248~9 1997-12-17 W O 97~9032 PCT~US97/06503 IGF-I, IGF-II and binding proteins for use in such assays may generally be prepared by techniques known to those of ~rdill~ y skill in the art, such as those provided in Rechler, ~itamins and Hormones 4'7:1-114, 1993, and references citedtherein. Appropriate techniques include chemical synthesis (described, for example, in 5 Shim~ki et al., J. Biol. C~em. 266:10646-10653, 1991), purification from an aE~I,ropliate biological sample (described, for example, in Shimonaka et al., Biochem.
~iophys. Res. Comm. 165:189-195, 1989) and expression in a suitable host, such as yeast(described, for exarnple, in Bayne et al., ~ Biol. C~em. 265: 15648- 15652, 1990).
In this regard, the IGF and binding proteins employed may be the native proteins, or 10 may contain modifications, such as the addition of label or the addition or deletion of sequences that have minim~l effect on the binding properties of the protein. Antibodies suitable for use in ELISA assays are commercially available from, for example? Amano Pharmaceutical Co. or may be raised against the IGF and/or binding protein of interest by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., 15 Harlow and Lane, Antibodies. A l aboratory Man2~al, Cold Spring Harbor Laboratory, 1988. Monoclonal antibodies may be plepared, for example, using the technique ofKohler and Milstein, Eur. J. Immunol. 6:511 -519, 1976, and improvements thereto.
A secondary bioassay, based on the activity of the binding protein of interest, may also be employed for further characterization of a small molecule inhibitor 20 or other ligand inhibitor. For example, IGF-I stimulates 3T3 fibroblast proliferation in vi~ro. The addition of a binding protein inhibits this stimulation, and the level of inhibition can be deterrnined using [3H]thymidine incorporation assays well known to those of ordinary skill in the art. Molecules that are capable of reversing the binding protein inhibition are ligand inhibitors. Similar assays may be designed for use with 25 specific binding proteins based on the known biological properties of the binding proteins (e.g., the inhibition of granulosa cell steroidogenesis as described in Bicsak et al., Endocrinol. 126:2184-2189, 1990).
Animal models may be useful for further characterization of ligand inhibitors. For example, the effect of a ligand inhibitor on blood glucose levels may be 30 evaluated using ~nim~ such as rats. An inhibitor that normalizes blood glucose levels in hyperglycemic or diabetic animals may be useful for the treatment of diabetes.
CA 022248~9 1997-12-17 W O 97/39032 PCTrUS97/06503 Similarly, growth hormone deficient ~nim~l~ may be used to evaluate the utility of a ligand inhibitor for the treatment of conditions that respond to the ~fimini.~tration of ~ human growth horrnone, such as human growth hormone resistance.
Ligand inhibitors of the present invention may generally be used to 5 increase the level of free, biologically active IGF in a patient and to treat any of a variety of IGF-responsive conditions. The term "IGF-responsive condition"
encomr~ses any condition of a patient that may be alleviated or treated by the ~,lmini.stration of IGF, and includes diseases such as diabetes (insulin dependent, non-insulin dependent and type I/II), growth retardation, osteoporosis, human growth10 horrnone resistance, ALS, demyelinating diseases (including via remyelination), multiple sclerosis, muscular dystrophy, stroke, ophthalmic conditions, infertility, Alzheimer's disease and other dementias. The terrn "IGF-responsive condition" also encomp~cses states in which it is desirable to induce wound healing or bone repair, such as bone remodeling. As used herein, a "patient" refers to any warm-blooded 15 animal, preferably a human. A patient may or may not be afflicted with an IGF-responsive condition. Patients that are so afflicted may generally be identified through clinical diagnosis according to methods that are well known to those of ordinary skill in the art.
Within the context of the present invention, the minimum acceptable 20 increase in the level of free IGF is 10%, a preferred level is at least 50% and a particularly preferred level is at least ~0%. The level of free IGF may generally be determined by methods known in the art, such as resolving the plasma sample to different molecular size fractions on a Sephadex G-50 fine column developed in 0.02M
potassium phosphate buffer, pH 7.2. The free IGF-I with a molecular weight of 7.6 25 kDa will elute later than the larger molecular weight IGF-IIIGFBP complex. The free IGF-I fraction can then be quantitated by radioimmunoassay. Alternatively, bloodglucose levels may be used as an indirect measurement of free IGF levels.
Other techniques, such as MRI, PETSCAN, spect~c~nning or other similar im~ging techniques, may also be employed to measure the increase in the level 30 of free IGF. Some of these techniques use radiolabeled ligand to IGF binding proteins or IGF receptors. A preferred method is image analysis using PET positron-emitting CA 022248~9 1997-12-17 wO 97/39032 PCT/US97/06503 ligands (e.g., "C or '8F) of a single photon-emitting ligand (e.g, l23I-labeled ligand to IGF-binding proteins or IGF receptors). Free IGF levels are correlated to the amount of binding of the radiolabeled ligand. An increase in IGF levels is manifested by adecreased binding of the radiolabeled ligand to the IGF-binding proteins and IGF5 receptors. Within this im~ging technique, an increase in free IGF levels of about 10-30% or more is sufficient.
For ~-lmini~ration to a patient, the ligand inhibitors are preferably incorporated into pharmaceutical compositions, which comprise a therapeutically effective amount of one or more ligand inhibitors and a physiologically acceptable 10 carrier. A "physiologically acceptable carrier" may be any composition, carrier or diluent that is capable of aAmini~tration to a m~mm~l without producing undesirable physiological effects, such as nausea, dizziness or gastric upset. While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending 15 on the mode of allministration. In general, the pharmaceutical compositions may be ~lmini.~tered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g, by aspiration) or orally. For parenteral a~lmini.~tration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax and/or a buffer. For oral ~lmini.ctration, any of the above carriers and/or a 20 solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed.
Small molecule inhibitors of the present invention are preferably capable of oral atlmini.stration in, for example, capsule or tablet form. Such ligand inhibitors have the advantage of decreased cost and increased convenience, as compared to 25 conventional treatments that rely on repeated intravenous injection. In general, the ability of a small molecule inhibitor to be a~mini~tered orally may be determined by in vivo assays. Such assays typically measure the decrease in the level of IGF bound to binding proteins in response to oral ~flmini~tration of the small molecule inhibitor. For example, the amount of small molecule inhibitor in the blood may be measured based 30 on its ability to inhibit binding of '25I-hlGF-I to IGF binding proteins. Blood samples may be drawn at various times after a~lmini.~tration of small molecule inhibitor or CA 022248~9 1997-12-17 W O 97139032 PCT~US97/06503 vehicle to ~nim~l~ or humans. If necessary, the ligand inhibitor may be extracted from the blood by standard procedures (e.g., ~0% acetonitrile/0.1% trifluoroacetic acid).
Briefly, 1 mL of the extraction solvent may be added to 200 IlL of plasma and the mixture is vortexed. The resultant precipitate may then be centrifuged at 12,000 x g for 5 5 minutes. The supernatant cont~ining the ligand inhibitor may then be Iyophilized and reconstituted in assay buffer (PBS cont~ining 0.2% Nonidet p 40TM) to yield a reconstituted extract. Blood samples or reconstituted extracts may then be used in a binding assay, such as that described in Example l, below. Ligand inhibitors capable of oral ~lm;ni~tration will show inhibition of binding of '25I-hIGF-I to IGF binding 10 proteins, relative to the vehicle control.
Routes and fre4uency of ~(lministration, as well as dosage, will vary depending on the ligand inhibitor and the desired in vivo response. A suitable dose is an amount of ligand inhibitor that, when a~1mini~tered as described above, is capable of improving the clinical outcome for a patient (e.g, fewer hypoglycemic episodes for 15 diabetic patients) in treated patients as compared to untreated patients.. ln general, for pharmaceutical compositions comprising one or more ligand inhibitors, the amount of each ligand inhibitor present in a dose ranges from about 0.1 to about 10, preferably from about 1 to about 3 mg/kg. A larger or smaller amount may, however, be employed, depending on the size of the ligand inhibitor. Treatments are typically 20 conducted one-two times per day, and may need to be continuous for retention of benefit. Patients may be monitored by assessing IGF levels as described above and by evaluating clinical symptoms.
A significant advantage of the present invention lies in the ability to vary the potency of the ph~rm~r.eutical composition and to target IGF effects to specific 25 tissues, minimi7ing side effects. The potency may be varied through the use of ligand inhibitors with varying abilities to inhibit the binding of IGF to one or more binding proteins. In this regard, the relative abilities of ligand inhibitors to inhibit binding may be evaluated by, for example, comparing the amount of inhibitor needed for half maximal displacement of specific binding in all in vitro binding assay as described 30 herein.
CA 022248~9 l997-l2-l7 W O 97139032 PCTfUS97/06503 IGF effects may be targeted by using ligand inhibitors that are specific for one or more particular binding proteins, and exploiting the relative tissue specificity of each of the six known binding proteins (see Rech}er, Vi~am~ns and Hormones 47:1-114, 1993). Binding protein-specific ligand inhibitors may be developed, as noted 5 above, by using different binding proteins within the binding assay described herein for the identification of small molecule inhibitors. Administration of such ligand inhibitors results in the release of IGF in only those tissues that contain the targeted binding proteins. For example, IGFBP-2, -4 and -6 are more prevalent in the brain. In addition, IGFBP-1 is present in the brain, although at lower concentrations. Small molecule 10 inhibitors that are specific for these binding proteins and are capable of crossing the blood/brain barrier (as discussed below) will release IGF in the brain, while leaving most of the serum IGF in its inactive form. Such inhibitors may be particularly useful for the treatment of ALS and other neurodegenerative diseases such as multiple sclerosis, demyelin~ting disease and Alzheimer's disease. Alternatively, peripheral 15 effects may be manipulated using primarily IGFBP-I, -3, -4, and -5. As noted above, circulating IGF-I may be released by inhibiting binding to IGFBP-3. In this regard, small molecule inhibitors that are not capable of crossing the blood/brain barrier are particularly well suited for providing peripheral effects.
The amount of a small molecule inhibitor that crosses the bloodlbrain 20 barrier may be assessed by techniques known to those of ordinary skill in the art, such as MRI, PETSCAN, spect~c~nnin~ or other similar im~gin~ techniques, some of which use radiolabeled ligand to IGF binding proteins or IGF receptors. As noted above, a preferred method is image analysis using PET positron-emitting ligands (e.g., "C or l8F) of a single photon-emitting ligand (e.g., '23I-labeled ligand to IGF-binding proteins 25 or IGF receptors). Decreased binding of the radiolabeled ligand to the IGF-binding proteins and IGF receptors indicates an increase in IGF levels. Such decreased binding is indicative of the level of small molecule inhibitor that has crossed the blood/brain barrier. Alternatively, IGF-I levels in the cerebrospinal fluid (CSF) can be measured by radioimmunoassay using commercially available assay kits (e.g, Peninsula 30 Laboratories, Inc., Belmont, CA) or by polyethylene/glycol precipitation, as described CA 022248~9 l997-l2-l7 in Example 1. An increase in the level of IGF-I in the CSF is indicative of an increase in the level of IGF-I in the brain.
In ~nim~l~, the blood/brain penetration of the small molecule inhibitors can be tested by ex vivo binding. Briefly, ~nim~ls may be injected (intravenously or 5 orally) with 15-50 mg/kg of a small molecule ligand inhibitor. The ~nim~l~ are then sacrif1ced at 15, 30, 60 and 90 minutes after ~-lmini.~tration of the drug. The brains are removed and homogenized in solubilization buffer (PBS cont~ining 0.2% Nonidet p 40TM detergent). The assay is then carried out by polyethyleneglycol pleci,oil~tion of the bound '2sI-hIGF/hIGFBP-3 complex. If any dru-g is present in the brain, it will 10 inhibit binding of the '25I-hIGF-I to the IGF binding proteins? resulting in fewer precipitated counts in the drug-treated animals than in :~nimz~ treated with vehicle alone.
Those of ordinary skill in the art will recognize that other tissues, and thus other IGF responsive conditions, may be targeted by ~-lmini~tering ligand 15 inhibitors specific for other binding proteins, or combinations thereof. The tissue distribution of the six known IGF binding proteins is presented in Table I, below:
Table I
Primary Tissue Distribution of IGF Bindin~ Proteins IGF Binding Protein Tissues BP- I placenta, liver BP-2 CSF, CNS, liver BP-3 ovary, adrenal, heart, kidney, liver, stomach, intestine BP-4 liver, brain cortex BP-5 liver, brain, lung, heart, spleen, stomach, kidney, adrenal, intestine BP-6 CSF and all tissue The following Examples are offered by way of illustration and not by way of limitation.
CA 022248~9 1997-12-17 W O 97139032 PCT~US97/06503 EXAMPLES
Example 1 5 Inhibition of IGF/BP-3 Bindin~ Usin~ hIGF-I Analo~s This Example illustrates the in vitro and in vivo inhibition of binding of IGF-I to BP-3, resulting in increased levels of free, biologically active IGF-I.
10 A. In vitro Bindin~ Assay The binding assay was performed in duplicate at room temperature in 0.2% BSA-PBS, pH 7.2. BP-3 was purified from rat serum as described in Shimonakaet al., ~iochem. Biophys. Res. Comm. 165:189-195, 1989. Two hundred microliters of a 2.5 nM BP-3 solution (0.5 pmol) was added to a 12 x 75-mm glass tube. The reaction 15 was started by the addition of an increasing concentration of unlabeled [T59]hIGF-I or [L24,S9,60,A31]hIGF-I (both prepared by chemical synthesis according to the procedure described in Shim~ki et al., J. Biol. Chem. 266:10646-10653, 1991) in 100 ~L followed by 100 ~L of '25I-labeled [T59]hIGF-I (30,000 cpm/~0.3 ng). After incubation for 2.5 hours, 100 ~L of 20% BSA and 500 IlL of 20% PEG-8000 in 20 phosphate buffered saline (PBS) was added and the mixture was vortexed and then centrifuged for 30 minutes at 3500 rpm. The supernatant was carefully removed bysuction and the pellet counted in a gamma counter.
As shown in Figure 1, 0.5 pmol of IGFBP-3 could bind 23.3% of the '2sI-labeled IGF-I tracer, and the non-specific binding was 1.8%. Half-maximal 25 displacement of the specific binding was achieved at approximately 0.32 pmol [T59~hIGF-I per tube and 0.8 pmol ~L24,59,60,A31]hlGF-I per tube (Figure 1).
This assay may also be employed to screen for small molecule ligand inhibitors.
CA 022248~9 1997-12-17 W O 97/39032 PCTrUS97/06S03 B. r3Hl-ThYmidine Incorporation Assay BALB/c 3T3 cells were trypsanized and diluted to 50,000 cells per mL
in 10% calf serum-DMEM. The cells were aliquoted to 96-well microtiter plates (180 ~L/well). After 48 hours incubation at 37~C and 5% CO2, the plates were washed twice S with 0.1% calf serum-DMEM and incubated for an additional 24 hours. To each well, 20 ~L of sample(s) cont~ining IGF analog and/or binding protein and I ~LCi [3H]-thymidine were added and the plates were incubated for precisely 24 hours. After the incubation, the medium was removed and the cells were fixed by adding 200 IlL of25% acetic acid-75% ethanol per well. After removal of the fixing solution the plates 10 were washed three times with cold 10% TCA and the cells in each well were lysed in 200 ~L 0.2M NaOH. The entire 200 IlL of lysed solution was transferred into a scintillation vial and 2.5 mL scintillation liquid was added and the vials counted in a ,~-counter.
[T59]hIGF-I dose dependently stimulated proliferation, as measured by 15 DNA synthesis, in 3T3 cells with a ED~o of 10-20 nM (Figure 2), whereas [L24,59,60,A31]hIGF-I did not induce any DNA synthesis in 3T3 cells with a dose as high as 8,000 nM (Figure 2). After incubation with 10 nM [T59]hIGF-I, the incorporated [3H]-thymidine in the 3T3 cells was increased 4-fold in comparison with the control (Figure 3). Incubation with 25 nM IGFBP-3 completely inhibited the [3H]-20 thymidine incorporation induced by 10 nM [T59]hIGF-I ~Figure 3~. Addition of [L24,59,60,A31]hIGF-I (which only binds to IGFBP-3, and not to the IGF-I receptors) could totally reverse the blocking effect of 25 nM IGFBP-3 to release the [T59~hIGF-I
bioactivity with a EDso of about 25 nM [L24,59,60,A31]hIGF-I (Figure 3).
This assay may also be employed to evaluate the biological activity of 25 small molecule ligand inhibitors.
CA 022248~9 1997-12-17 W O 97/39032 PCT~US97/06503 Example 2 Norm~1i7~tion of Blood Glucose Levels in Hyper~lvcemic Rats usin~ IGFBP-3 Inhibitor This Exarnple illustrates the use of ligand inhibitors of IGFBP-3 for the treatment of ~nim~ with elevated blood glucose.
Rats were made hyperglycemic with an intraperitoneal injection of glucose. The ~L24,59,60,A31]hIGF-I analog (noted as IGFBP3-LI) (S~lg/min) was infused intravenously for 40 minutes and blood glucose levels were monitored before, 10 during and after the infusion. As a control, bovine insulin was infused at 1 ~Lg/min for 40 minutes and blood glucose was monitored at the sarne time points.
As depicted in Figure 5, while the insulin dramatically lowered blood glucose levels below the normal baseline, making the Anim~ hypoglycemic, the [L24,59,60,A31]hIGF-I analog surprisingly normalized blood glucose levels. In a 15 related experiment, insulin dramatically decreased blood glucose levels on a normal fasted blood glucose baseline, but [L24,59,60,A31]hIGF-I had no effect.
These results indicate that [L24,59,60,A31]hIGF-I can normalize blood glucose levels in animals with elevated blood glucose but, unlike insulin, this analog does not decrease the blood glucose levels below the normal baseline and make the 20 ~nimz~ hypoglycemic. Thus, the use of inhibitors of IGF binding to IGFBP-3 have distinct advantages over insulin for the treatment of diabetes. Diabetics receiving insulin normally experience a rebound effect after intravenous insulin injection such that blood sugar levels fall below normal levels. The inhibitors of the present invention normalize blood sugar levels without the risk of hypoglycemia. In addition, both25 insulin dependent and non-insulin dependent diabetics may be treated.
CA 022248~9 1997-12-17 W 097/39032 PCTfUS97106S03 ExamPle 3 Norm~li7~tion of Blood Glucose Levels in Diabetic Mice using IGFBP-3 Inhibitor S This Example illustrates the use of ligand inhibitors of IGFBP-3 for the treatment of diabetes in ~nim~
Two severely diabetic female NOD mice with blood glucose levels of 450-500 mg/dl were treated with the [L24,59,60,A31]hIGF-I analog. These mice were severely diabetic and were expected to die within two days without treatment. The 10 [L24,59,60,A31]hlGF-I analog was a~mini.~tered at time 0 (25 ~Lg/animal). at 30 minutes (50 ~Lg/animal) and at 60 min (100 ~lg/animal) by tail vein injection inphysiological saline). Blood glucose levels were monitored using a glucometer before the initial injection and throughout the time course of the experiment.
In both ~nim~l~, the blood glucose levels decreased dramatically to 250 15 mg/dl after 80 minutes (Figure 4). Since the threshold for normal blood glucose is 220 mg/dl, the blood glucose levels were almost normalized in both ~nim711~. These results demonstrate that the [L24,59,60,A31]hIGF-I analog may be used to lower blood glucose levels in the treatment of diabetes.
From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the purpose of illustration, various modifications may be made without deviating from the spirit and scope of the invention.
CA 022248~9 1997-12-17 W O 97/39032 PCTrUS97106503 SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANTS: DOMINIC P. BEHAN, NICHOLAS LING, XIN-JUN LIU AND
AMITABH GAUR
(ii) TITLE OF INVENTION: LIGAND INHIBITORS OF INSULIN-LIKE GROWTH
FACTOR BINDING PROTEINS AND METHODS OF USE THEREFOR
(iii) NUMBER OF SEQUENCES: 2 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: SEED and BERRY LLP
(B) STREET: 6300 Colu~bia Center. 701 Fifth Avenue (C) CITY: Seattle (D) STATE: Washington (E) COUNTRY: USA
(F) ZIP: 98104-7092 (v) COMPUTER READABLE FORM.
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA:
(A) APPLICATTON NUMBER:
(B) FILING DATE: 17-APR-1996 (C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Maki, David J.
(B) REGISTRATION NUMBER: 31,392 (C) REFERENCE/DOCKET NUMBER: 690068.425 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (206) 622-4900 (B) TELEFAX: (206) 682-6031 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
CA 022248~9 1997-12-17 W 097/39032 PCT~US97/06503 (A) LENGTH: 70 amino acids (B) TYPE: amino acid (C~ STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu Lys Pro Ala Lys Ser Ala (2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 70 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe Val Cys Gly Asp Arg Gly Phe Leu Phe Asn Lys Pro Thr Gly Ala Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Leu Leu Cys Ala Pro Leu Lys Pro Ala Lys Ser Ala
Claims (26)
1. A ligand inhibitor that inhibits the binding of an insulin-like growth factor to one or more insulin-like growth factor binding proteins, for use within a method for increasing the level of free, biologically active insulin-like growth factor in a patient.
2. The ligand inhibitor of claim 1 wherein the ligand inhibitor is [L24,59,60,A31]hIGF-I or a variant thereof that differs only in conservative substitutions and/or modifications.
3. The ligand inhibitor of claim 1 wherein the ligand inhibitor is a small molecule inhibitor.
4. The ligand inhibitor of claim 1 wherein the level of free, biologically active insulin-like growth factor increases in the patient's blood.
5. The ligand inhibitor of claim 1 wherein the level of free, biologically active insulin-like growth factor increases in the patient's brain.
6. The ligand inhibitor of claim 1 wherein the insulin-like growth factor is IGF-I.
7. The ligand inhibitor of claim 1 wherein the insulin-like growth factor is IGF-II.
8. The ligand inhibitor of claim 1 wherein the insulin-like growth factor binding protein is IGFBP-3.
9. The ligand inhibitor of claim 1 wherein the insulin-like growth factor binding protein is selected from the group consisting of IGFBP-1, IGFBP-2, IGFBP-4, IGFBP-5, IGFBP-6 and combinations thereof.
10. A ligand inhibitor that inhibits the binding of an insulin-like growth factor to one or more insulin-like growth factor binding proteins, for use within a method for treating an IGF-responsive condition in a patient.
11 . The ligand inhibitor of claim 10 wherein the ligand inhibitor is [L24,59,60,A31]hIGF-I or a variant thereof that differs only in conservative substitutions and/or modifications.
12. The ligand inhibitor of claim 10 wherein the ligand inhibitor is a small molecule inhibitor.
13. The ligand inhibitor of claim 10 wherein the insulin-like growth factor is IGF-I.
14. The ligand inhibitor of claim 10 wherein the insulin-like growth factor is IGF-II.
15. The ligand inhibitor of claim 10 wherein the insulin-like growth factor binding protein is IGFBP-3.
16. The ligand inhibitor of claim 10 wherein the insulin-like growth factor binding protein is selected from the group consisting of IGFBP-1, IGFBP-2, IGFBP-4, IGFBP-5, IGFBP-6 and combinations thereof.
17. The ligand inhibitor of claim 10 wherein the IGF-responsive condition is selected from the group consisting of diabetes, growth retardation osteoporosis, human growth hormone resistance, wounds, bone damage, ALS, Alzheimer's disease, demyelinating disease, multiple sclerosis, muscular dystrophy, stroke and neuronal degeneration.
18. A pharmaceutical composition, comprising:
(a) one or more ligand inhibitors that inhibit the binding of an insulin-like growth factor to one or more insulin-like growth factor binding proteins; and (b) a physiologically acceptable carrier.
(a) one or more ligand inhibitors that inhibit the binding of an insulin-like growth factor to one or more insulin-like growth factor binding proteins; and (b) a physiologically acceptable carrier.
19. A pharmaceutical composition according to claim 18 wherein the ligand inhibitor is [L24,59,60,A31]hIGF-I or a variant thereof that differs only in conservative substitutions and/or modifications.
20. A pharmaceutical composition according to claim 18 wherein the ligand inhibitor is a small molecule inhibitor.
21. A method for screening for a small molecule inhibitor that inhibits binding of an insulin-like growth factor to an insulin-like growth factor binding protein, comprising:
(a) combining an insulin-like growth factor with an insulin-like growth factor binding protein in a solution containing a candidate small molecule, such that the binding protein and the growth factor are capable of forming a complex; and (b) determining the amount of complex in the solution, relative to a predetermined level of binding in the absence of the small molecule, and therefrom evaluating the ability of the small molecule to inhibit binding of an insulin-like growth factor to an insulin-like growth factor binding protein.
(a) combining an insulin-like growth factor with an insulin-like growth factor binding protein in a solution containing a candidate small molecule, such that the binding protein and the growth factor are capable of forming a complex; and (b) determining the amount of complex in the solution, relative to a predetermined level of binding in the absence of the small molecule, and therefrom evaluating the ability of the small molecule to inhibit binding of an insulin-like growth factor to an insulin-like growth factor binding protein.
22. The method of claim 21 wherein the insulin-like growth factor is IGF-I.
23 . The method of claim 21 wherein the insulin-like growth factor binding protein is IGFBP-3.
24. The method of claim 21 wherein the insulin-like growth factor binding protein is selected from the group consisting of IGFBP-1, IGFBP-2, IGFBP-4, IGFBP-5, IGFBP-6 and combinations thereof.
25. A ligand inhibitor that inhibits the binding of the protein to one or more insulin-like growth factor binding proteins, for use within a method for increasing the level of a free, biologically active protein in a patient.
26. A ligand inhibitor that inhibits the binding of insulin-like growth factor to one or more insulin-like growth factor binding proteins, for use within a method for increasing the level of free IGF-II in a patient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63393496A | 1996-04-17 | 1996-04-17 | |
US08/633,934 | 1996-04-17 | ||
PCT/US1997/006503 WO1997039032A1 (en) | 1996-04-17 | 1997-04-17 | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2224859A1 true CA2224859A1 (en) | 1997-10-23 |
Family
ID=24541756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002224859A Abandoned CA2224859A1 (en) | 1996-04-17 | 1997-04-17 | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0854884A1 (en) |
JP (1) | JPH11508608A (en) |
AU (1) | AU2676297A (en) |
CA (1) | CA2224859A1 (en) |
WO (1) | WO1997039032A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0965596A1 (en) | 1996-12-27 | 1999-12-22 | Daiichi Pharmaceutical Co., Ltd. | Method for elevating the concentration of free insulin-like growth factor |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
US7288516B1 (en) | 1999-09-20 | 2007-10-30 | Celtrix Pharmaceuticals, Inc. | Null IGF for the treatment of cancer |
DK1141014T3 (en) | 1999-01-06 | 2005-04-11 | Genentech Inc | Insulin-like growth factor (IGF) in mutant variant |
AU762047B2 (en) | 1999-01-06 | 2003-06-19 | Genentech Inc. | Insulin-like growth factor (IGF) I mutant variants |
ES2266187T3 (en) | 2000-03-24 | 2007-03-01 | Genentech, Inc. | USE OF INSULIN FOR THE TREATMENT OF CARTILAGO DISORDERS. |
ATE389416T1 (en) | 2000-05-16 | 2008-04-15 | Genentech Inc | TREATMENT OF CARTILARY DISEASES |
AU2002246619A1 (en) * | 2000-12-08 | 2003-06-23 | Neuronz Limited | Use of insuline-like growth factor-i for promoting remyelination of axons |
US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
AU2002303856A1 (en) | 2001-05-24 | 2002-12-03 | Neuronz Limited | Gpe analogs and peptidomimetics |
EP2425823A1 (en) * | 2002-04-05 | 2012-03-07 | Euro-Celtique S.A. | Pharmaceutical preparation containing oxycodone and naloxone |
ATE536186T1 (en) | 2003-09-12 | 2011-12-15 | Tercica Inc | METHOD FOR TREATING IGF-1 (INSULIN-LIKE GROWTH FACTOR 1) DEFICIENCY |
BR112012029611A2 (en) | 2010-05-21 | 2017-07-25 | Merrimack Pharmaceuticals Inc | bispecific fusion protein, pharmaceutical composition, method of treating tissue damage in an individual, method of promoting tissue regeneration or survival in an individual, and nucleic acid molecule |
MX2017015700A (en) * | 2015-06-04 | 2018-11-09 | Ospedale San Raffaele Srl | Igfbp3 and uses thereof. |
MX367312B (en) * | 2015-06-04 | 2019-08-14 | Ospedale San Raffaele Srl | Inhibitor of igfbp3/tmem219 axis and diabetes. |
EP3865147A1 (en) | 2015-10-02 | 2021-08-18 | Silver Creek Pharmaceuticals, Inc. | Bi-specific therapeutic proteins for tissue repair |
WO2021005604A1 (en) | 2019-07-11 | 2021-01-14 | Opko Biologics Ltd. | Long-acting igf-1 or igf-1 variants and methods of producing same |
WO2022216944A1 (en) * | 2021-04-07 | 2022-10-13 | Mayo Foundation For Medical Education And Research | Methods and materials for reversing atherogenic plaque instability |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985000831A1 (en) * | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of insulin-like growth factor |
-
1997
- 1997-04-17 WO PCT/US1997/006503 patent/WO1997039032A1/en not_active Application Discontinuation
- 1997-04-17 JP JP9537398A patent/JPH11508608A/en active Pending
- 1997-04-17 CA CA002224859A patent/CA2224859A1/en not_active Abandoned
- 1997-04-17 AU AU26762/97A patent/AU2676297A/en not_active Abandoned
- 1997-04-17 EP EP97918725A patent/EP0854884A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP0854884A1 (en) | 1998-07-29 |
MX9710291A (en) | 1998-08-30 |
JPH11508608A (en) | 1999-07-27 |
AU2676297A (en) | 1997-11-07 |
WO1997039032A1 (en) | 1997-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2224859A1 (en) | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor | |
Baxter et al. | Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia | |
JP6581606B2 (en) | Exendin-4 derivatives as selective glucagon receptor agonists | |
AU634954B2 (en) | Treatment of diabetes mellitus | |
DE60016560T2 (en) | MUTED VARIANT OF INSULIN-SIMILAR GROWTH FACTOR-I (IGF-I) | |
CN107921085B (en) | Methods and compositions for treating aging-related disorders | |
US20050176621A1 (en) | Crystalline compositions for controlling blood glucose | |
US6610649B2 (en) | Insulin C-peptides | |
US20110195896A1 (en) | Isoform-specific insulin analogues | |
US9149510B2 (en) | Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes | |
US20050054818A1 (en) | Crystalline compositions for controlling blood glucose | |
JP2009542217A (en) | Glucagon-like peptides and uses thereof | |
US20100216693A1 (en) | Compositions and methods of treating diabetes | |
JP2002521458A (en) | Method for treating polycystic ovary syndrome using IGF / IGFBP-3 | |
CN116322739A (en) | GLP-1R agonist/FGF 21 fusion proteins | |
EP0580752A1 (en) | Human bone derived insulin like growth factor binding protein | |
AU1014400A (en) | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor | |
WO1993021945A1 (en) | METHODS FOR TREATING VASCULAR DISORDERS BY INHIBITING THE ENDOTHELIN STIMULATORY ACTIVITY OF TGF$g(b) | |
JP2003522110A (en) | Null IGF for cancer treatment | |
KR102673860B1 (en) | Novel Peptide Having Activity of Improving Dry Eye Disease and Uses Thereof | |
WO1999049894A1 (en) | Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders | |
MXPA97010291A (en) | Binding inhibitors of insulin type growth confactor fixation proteins and methods of use for myself | |
WO2022262837A1 (en) | Glucagon analog and medical use thereof | |
RU2523416C2 (en) | Using somatostatin analogues in meningioma | |
JP2017532292A (en) | Myristoylated leptin-related peptides and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |